Qualigen Therapeutics is a life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. Co.'s drug compound QN-302 is being developed to target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways for treatment of G4-targeted tumors. The investigational compounds within Co.'s RAS portfolio are designed to suppress the interaction of endogenous RAS with c-RAF, upstream of the KRAS, HRAS and NRAS effector pathways. Co.'s anticancer drug candidate, QN-247 is aptamer-based to treat a variety of cancer types, including liquid and solid tumors. The QLGN stock yearly return is shown above.
The yearly return on the QLGN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the QLGN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|